TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A physician’s commentary published October 27, 2026, argues that persistent subjective cognitive decline can be a reason to establish a detailed cognitive baseline and follow changes over time, even when test scores remain within the normal range. Subjective decline is not a diagnosis of Alzheimer’s: sleep, mood, medication and other health factors can contribute, and the supplied article excerpt does not provide the full discussion of biomarker testing.
Geriatrician Nathaniel Chin says people who report lasting changes in memory or thinking should not automatically be told to wait for test scores to worsen: in a commentary published October 27, 2026, he argues that a careful baseline assessment and follow-up may help clinicians understand those changes earlier. He stresses that subjective cognitive decline is not an Alzheimer’s diagnosis, and that normal scores do not establish the cause of a person’s concern.
Chin defines subjective cognitive decline (SCD) as a person’s persistent sense that their thinking has worsened from their prior level, despite comprehensive testing showing no objective impairment. People may describe forgetting conversations, depending more on notes, or needing greater effort to think. A normal result can be reassuring about measured performance, but it may not capture a meaningful change from that individual’s earlier abilities.
The commentary distinguishes a brief screening from a comprehensive cognitive evaluation. Screening tests generally take five to 15 minutes and sample a limited range of abilities. A more extensive assessment usually takes an hour or longer and examines areas such as memory, language, attention and executive function. Chin says careful testing matters because SCD should be considered only after objective impairment has been assessed adequately.
He also recommends looking beyond a single score. A person may remain within the average range while declining from a much higher prior level, he writes. Repeated testing can help show whether performance is stable or changing over time. His proposed clinical approach for persistent concerns includes establishing a detailed baseline, checking for other possible contributors, seeking observations from someone who knows the person when possible, and repeating assessments.
Why Normal Scores May Miss Change
Chin’s argument is that a normal test result and a person’s report of change are not necessarily contradictory. Many tests compare someone with peers of a similar age rather than with their own earlier abilities. A person can lose ground relative to their personal baseline and still score in the expected range. That gap can matter for clinical follow-up, but it does not prove Alzheimer’s disease.
The practical implication is a more measured response than either dismissing concerns or assuming the worst. Persistent reports may warrant a fuller evaluation and a plan to track cognition, while clinicians also consider sleep, mood, medicines and medical conditions. For readers, the distinction is important: SCD describes an experience, not its cause, and the commentary does not claim that every person reporting memory changes is on a path to dementia.
Earlier assessment can also help make uncertainty explicit. A baseline may give a clinician and patient a reference point for later visits; gathering a trusted person’s observations can add information about changes in daily life. These steps are presented as ways to assess and monitor concerns, not as a guarantee that Alzheimer’s can be prevented or treated during this period.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Bonus Bands
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Fitbit Versa 4 Fitness Smartwatch – Black/Graphite
As an affiliate, we earn on qualifying purchases.
How Clinicians Define SCD
Chin is a geriatrician and memory-care physician at UW Health, an associate professor at the University of Wisconsin–Madison, and medical director and Clinical Core co-leader of the Wisconsin Alzheimer’s Disease Research Center. The source article presents his views as a physician’s commentary, rather than as results from a new clinical trial or a newly published research study.
The commentary describes a set of features known as “SCD plus,” developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. These features include memory-focused concerns, onset within the past five years or at age 60 or older, worry, persistence, seeking medical help, and confirmation by someone who knows the person well. Chin says no single feature proves Alzheimer’s; several occurring together may justify closer attention.
He contrasts a long-standing, intermittent concern linked to stress or poor sleep with a newer, persistent memory change that worries the person and is also noticed by a spouse. Both people might receive normal scores, he writes, but the pattern and timing would lead him to consider their situations differently. The comparison illustrates a clinical judgment, not a diagnostic rule.
What SCD Cannot Establish
The cause of a reported change cannot be determined from SCD alone. Chin lists sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging as possible influences on how sharp thinking feels. The presence of one or more SCD-plus features may prompt closer attention, but the article says these features do not confirm Alzheimer’s.
The supplied source excerpt begins a discussion of blood biomarkers, cerebrospinal fluid testing and amyloid PET, asking whether they can detect Alzheimer’s before cognitive impairment. It cuts off before giving the physician’s explanation, evidence, patient-selection criteria or limitations. No conclusions about the accuracy, availability or appropriate use of those tests can be drawn from the material provided.
The excerpt also does not report study findings, treatment outcomes or evidence that acting during SCD prevents Alzheimer’s. The article’s headline refers to prevention and treatment, but the available text supports a narrower claim: Chin sees persistent subjective concerns as a possible opportunity for assessment and monitoring. Whether a particular person’s symptoms reflect Alzheimer’s or another cause remains a matter for clinical evaluation.
Monitoring Concerns Over Time
Chin’s suggested next steps are to assess persistent concerns carefully, check for other potential contributors and compare cognition across visits. Where appropriate, input from a person who knows the patient may help describe whether a change is visible in daily life. Repeat testing can then show whether measured performance remains stable or changes. The commentary does not set a universal follow-up schedule.
For readers experiencing ongoing changes, the article supports raising those concerns with a qualified health professional rather than treating a normal brief screen as a complete explanation. A clinician can decide whether a more extensive assessment or further investigation is appropriate. The source material provides no specific timeline or announced next milestone for biomarker testing, treatment decisions or research results.
Key Questions
What is subjective cognitive decline?
SCD is a persistent feeling that one’s memory or thinking has worsened compared with an earlier level, even though comprehensive cognitive testing does not show objective impairment. It describes a concern, not its cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD does not mean Alzheimer’s disease. Sleep, mood, medications, illness, hearing loss, stress and normal aging can also affect how a person experiences their thinking.
Why might a person have normal test results but still notice a change?
Tests commonly compare a person with others of similar age, not with their own earlier abilities. Someone may decline from a higher personal baseline while still scoring within the expected range, according to Chin.
What does “SCD plus” refer to?
It is a group of features, including persistent or memory-focused concerns, worry, recent onset, seeking medical help and confirmation by someone close to the person. Chin says these features do not prove Alzheimer’s, though several together may warrant closer assessment.
What does the source say about Alzheimer’s biomarkers?
The supplied excerpt names blood tests, cerebrospinal fluid testing and amyloid PET as methods raised in the article’s discussion, but it ends before explaining them. It therefore does not establish when they should be used or what their results mean for an individual.
Source: beingpatient.com
